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Abstract
Background: Managing inter-fractional anatomy changes is a challenging task in radiotherapy of pancreatic
tumors, especially in scanned carbon-ion delivery. This treatment planning study aims to focus on clinically feasible
solutions, such as the beam angle selection and margin design to increase the robustness against inter-fractional
uncertainties.
Methods: This study included 10 patients with weekly 3D-CT imaging and physician-approved Clinical Target
Volume (CTV). The study was directed to keep the CTV-coverage using six beam angle configurations in combination
with different Internal Target Volume (ITV) concepts. These were: geometric-margin (symmetric 3 and 5 mm margin);
range-equivalent margins with an isotropic HU replacement; and to evaluate the need of asymmetric margins the
water-equivalent range path (WEPL) was determined per patient from the set of CTs.
Plan optimization and forward dose calculation in each week-CT were performed with the research treatment
planning system TRiP98 and the plan quality evaluated in terms of CTV coverage (V95CTV) and homogeneity dose
(HCTV = D5-D95).
Results: The beam geometry had a substantial impact on the target irradiation over the treatment course, with
the single posterior or two beams showing the best average coverage of the CTV. The use of geometric margins
for the more robust beam geometries showed acceptable results, with a V95CTV of (99.2 ± 1.2)% for the 5 mm-margin.
For the non-robust configurations, due to substantial changes in the radiological depth, the use of this margin results
in a V95CTV that might be below 80%, only showing improvement when the range changes are included.
Conclusions: Selection of adequate beam configurations and treatment margins in ion-beam therapy of pancreatic
tumors is of great importance. For a single posterior beam or two beam configurations, application of geometrical
margins compensate for dose degradation induced by inter-fractional anatomy changes for the majority of the
analyzed treatment fractions.
Introduction
Pancreatic cancer is still a disease without an effective
treatment option usually with low survival rates and
local control [1]. For locally advanced tumors one of the
treatment schemes is photon radio-chemotherapy. How-
ever, a recent analysis showed that most tumor recur-
rences occur within a 2 cm radius of the primary tumor
[2], indicating the need of dose escalation to improve
the local control while keeping reduced side-effects.
Hence, an alternative is the use of ion-beam therapy
with proton or heavy ions [3]. Studies from the National
Institute for Radiological Sciences (NIRS) and at the
Heidelberg Ion-Beam Therapy Center (HIT) investigate
this assumption. NIRS studies about the dose escalation
and combined-chemotherapy with carbon-ions radio-
therapy have shown a strong increase in the tumor local
control and in the overall survival [4]. These results have
motivated the conduct of the Phoenix-Trial at HIT
which intends to use scanned carbon-radiotherapy to
downsize the tumor before surgery [5].
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The physical characteristics of the carbon-ions beam
offer the possibility for highly conformal treatments as
consequence from the reduced lateral scattering, the
finite range and the shape of the depth dose profile.
Moreover, from a radiobiological point of view, carbon-
ions exhibit a relative biological effectiveness (RBE) of
1.16-2.46 [6] for pancreatic tumor cells and a low oxygen
enhancement ratio, which due to the large fraction of
hypoxic cells in pancreatic tumors make them a promis-
ing treatment option [7].
However the finite range of ions is also a source of
uncertainties. The high sensitivity of the ion range to
density changes in the beam-path induces dose under-
and overshoots. These variations can either result from
inter-fractional anatomy changes, patient positioning or
intra-fractional motion [3].
Inter-fractional changes in pancreatic patients are mainly
due to tumor shrinkage organ filling (bowel and stomach)
and loss of adipose tissue [8]. These variations can be in-
cluded in the planning process through the use of safety
margins, although this compromises the dose to the normal
tissues and does not consider range changes. The selection
of the beam angles also affects plan quality and should
avoid density variations along the beam path, minimizing
the variations of the water-equivalent-path-length (WEPL).
Note, that the effect of tumour shrinkage is not avoided by
these methods, but its influence in the neighboring OARs
can be reduced through the use of robust beam configura-
tions, and its monitoring will help in the identification of
the need for plan adaptation.
Intra-fractional motion is caused by respiration [9] and
bowel movement [10] which besides range changes might
results in under- and over-dosage regions, as result from
the interference between the beam delivery and the target
motion (interplay) in scanned beam delivery systems.
This study focuses on the impact of inter-fractional
motion on the delivered dose during the pancreatic
treatment and on the development of clinically feasible
strategies to increase the treatment robustness by optimiz-
ing beam angles and internal margins. The investigation
of the effects of intra-fraction motion it is not within
the scope of this work and will be the subject of future
publications.
Methods
Patient dataset & imaging
For a set of ten patients which had already been treated
with photon radiotherapy, an in-silico analysis of the im-
pact of inter-fractional motion on the plan quality for
the treatment with scanned carbon-ions was performed.
All the patients were weekly CT imaged for positioning
verification purposes.
The four CT images were registered to the first week-CT
(considered here as the CTplan) through rigid registration.
Registration was validated using anatomical landmarks and
visual inspection.
Contouring and volume definition
All weekly-CTs included physician-approved contours of
the Gross Tumor Volume (GTV) and Clinical Target
Volume (CTV). The CTV was defined as the GTV plus
an isotropic margin of 5 mm. Details on the initial
CTV volume of each patient and its variation in volume
and location over the treatment are presented in the
Additional file 1: Table S.1. To incorporate inter-fractional
motion effects we investigated three approaches to define
an Internal Target Volume (ITV) for dose optimization:
 Geometrical ITVG: Geometric concept by
application of 3 and 5 mm symmetric margins to the
CTV volumes, ITVG3 and ITVG5, respectively.
Results were compared with the use of no additional
margin (ITVG0).
 Uniform range-margin ITVHU: Based on the
geometric concept (ITVG) a uniform range-margin
was introduced into the optimization by replacing
the HU values in an isotropic CTV-ITV margin of
3 or 5 mm with the patient-specific median density of
the pancreas. The volumes were defined as ITVHU3
and ITVHU5. In addition, also the areas inside the
ITVHU, in which the density was less than twice the
standard deviation of the median HU value, were
overwritten.
 Beam specific Water-equivalent-path length,
ITVWEPL: To assess the needed margin to overcome
the range uncertainties caused by anatomy variations
along the treatment, an ITV considering the changes
of the WEPL over the set of weekly-CTs, ITVWEPL,
was determined. To this end, we employed the
method defined by Graeff et al. [11], using the 4D
extension of the treatment planning system (TPS)
TRiP98 [12, 13], TRiP4D. In short, the HU changes
along the specific beam direction in the set of weekly-
CTs was converted into range changes, which led to
the ITVWEPL. The latter was then optimized on the
basis of these changes, to ensure adequate CTV
coverage for the whole imaging set.
The definition of a Planning Target Volume (PTV) was
out of the scope of this work as safety margins for set-up
uncertainties will be subject of a separate investigation.
Likewise intra-fractional motion uncertainties were also
not considered.
Treatment plan optimization and forward dose
calculations
Plans were optimized using the research TPS TRiP98 [13]
where the same beam base data and RBE input tables [12]
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were used as for our commercial system in clinical
use, Syngo® RT Planning (Siemens Oncology Care Sys-
tems, Germany). The optimization technique used was
intensity-modulated particle therapy (IMPT) with the
ITV as the target to get full coverage of the CTV with
a biological dose of 15 x 3 Gy (RBE). The biological
dose calculation uses the local effect model [14]. The
spinal cord, kidneys, stomach and bowel were consid-
ered organs-at-risk (OARs) and treatment plans were
tailored to respect the tolerances suggested by the lit-
erature [15]. The α/β-ratio equal to 2 was used for all
the various organs.
The IMPT optimization was performed with a reduced
number of constraints in a way to preserve relatively
high dose homogeneity in the single beams, preventing
high gradients in the target volume, and avoiding the
need of patch techniques. In the Additional file 1 a com-
parison between SFUD and IMPT plans for a set of pa-
tients is provided. This allows to demonstrate that IMPT
plans with comparable homogeneity to SFUD plans and
without compromising the plan quality can be achievable.
For each patient six different beam geometries were
optimized (Fig. 1) using pencil beams with 10 mm of
FWHM, a raster spacing of 3 x 3 mm in lateral direction
and an iso-energy slice spacing of 3 mm. Our raster
scanning technique is characterized by a synchrotron
spill structure of 5 s, a sweep time of 60 m/s and no
rescanning is currently implemented.
Based on the optimized plan for the CTplan the for-
ward calculation was performed for the following weeks
by application of the raster-scan sequence on the regis-
tered CT.
Data analysis
The CTV coverage was determined by the volume that
receives more than 95% of the prescribed dose (V95CTV).
Additionally the CTV homogeneity dose (HCTV) was cal-
culated by the difference of the dose given to 5% and 95%
of its volume, HCTV =D5 ‐D95.
The concept of the ITVWEPL was applied to evaluate
the need of asymmetrically defined ITV to increase the
plan robustness for patients under larger range changes.
Using the TPS TRiP4D the ITVWEPL was determined
per field from the set of weekly-CTs and contours. The
field-specific ITVWEPL was evaluated by comparison with
the CTV and ITVG5, through the volumetric changes
and the ratio of the overlapping volumes (Dice Similar-
ity Coefficient, DSC [16]). To extract the information
of the margins direction and size we evaluated the vari-
ation of the center of mass (COM) and the Hausdorff
distance (HD) between ITVWEPL and CTV [16], which
identifies the largest of all distances from one of the
contours to the closest point on the other contour [17].
To reduce the patient-specific influence when applying
this concept to other patients, the 95th percentile of the
HD was used as evaluation metric, HD95.
Results
The impact of anatomy and range changes on the target
coverage and dose homogeneity among beam geometries
margins concepts, patients, and fractions were analyzed.
Furthermore, the CTV and COM changes along the
treatment were analyzed and used to identify the reason
for the dose degradation (e.g. CTV shrinkage, shift of CTV
COM due to bowel volume, etc.). These data are available
in the Additional file 1. Figure 2 shows two examples of the
observed anatomical changes.
The plans with multiple beams showed an equally dis-
tributed and homogenous dose per beam i.e. each beam
contributes to the total dose with (50.0 ± 2.5)% of the
number of particles and a homogenous dose distribution
per beam is observed, as consequence of a moderate
IMPT optimization.
Inter-fractional changes and Beam Geometry Robustness
The beam geometry showed a substantial impact on tar-
get coverage and homogeneity over the treatment course
with the configuration C and D (Figs. 1 and 3) showing
Fig. 1 Plan parameters under evaluation. a Beam geometries with 1 field (A-D) and 2 fields (E,F). b Applied ITV-concepts in the optimization stage
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the worst average coverage as well as standard deviations
along the treatment (Table 1). These values are related
with the observed range uncertainties in the anterior ab-
domen region due to the inter-fractional variability of
the anatomy (bowel, stomach, weight loss). Figure 3 shows
the dose distribution impact in one of the follow-up CTs
for four patients as representative of these inter-fractional
changes contributors. V95CTV for non-robust geometries
decreased by up to 30% and 28%, for a 3 mm and 5 mm
margin, respectively. This extreme effect was detected, as
example, in a patient with larger weight loss (patient 8,
Fig. 3d) and in a case with strong bowel variation (e.g.
patient 3 and 10, Fig. 3a and c).
Impact of margins
The selection of robust beam geometries (as A B, E and F)
together with the use of geometric margins showed to be
able to mitigate some of the effects of the inter-fractional
Fig. 2 Overlay of the planning CT (red) and the CT of the week 5 (blue) for the patient 3 and 10. The grey color means perfect overlay between
the patient anatomy and the red/blue color the region with anatomy changes (i.e. bowel, stomach and weight loss). The dark blue contour
represents the planning CTV, while the light blue the CTV of the week 5 CT
Fig. 3 Forward dose distribution of the optimized plan for the ITVG5 (white contour) in one of the weekly CTs. Different inter-fractional changes
are disclosed for analysis of the CTV (blue) V95CTV: (a) Patient 3, for which the use of an anterior beam results in CTV under-dose due to changes
in the bowel/stomach, (b) Patient 6, the oblique posterior beam does not overcome the tumor shift and deformation. c Patient 10, irradiation with a
lateral right beam, where the range changes resulted from the bowel and liver position led to health tissues overdose. d Patient 8, an anterior beam is
not robust to the accentuated weight loss (visible the comparison of the distribution in the first and last week CT). e Dose distribution for the same CT
and patient as in the figure a) but showing the retrospectively determined ITVWEPL (black contour) in comparison to the ITVG5
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range changes, Table 1 and Fig. 4, where the use of the
ITVG5 was enough to keep the mean V95CTV above 99%.
From the outlier of the Fig. 4a) is concluded that even for
the more robust geometries there are cases of patients and
isolated fractions with dose degradation. The analysis of
these particular cases, was found to correspond to patients
with changes in the tumor volume and COM (e.g. Fig. 3b).
To overcome these situations the use of two oblique pos-
terior beams showed to be more robust.
Other analyzed option to increase the plan robustness
was the use of symmetric range-equivalent margins
ITVHU. The results (Table 1 and Fig. 4a) showed that the
used of 3 and 5 mm HU-uniform was not sufficient to
mitigate the extreme range changes in the anterior and
lateral beam direction, without significant improvement
over the geometric concept.
Asymmetric margin analysis
The obtained ITVWEPL that includes the range variations
along the weekly-CTs, represent how asymmetrically the
ITV needs to be defined to maintain the CTV coverage.
A representative example is shown in 3e.
The ITV size and shape necessary to keep the CTV
coverage does not need to be volumetrically larger than a
5 mm expansion with the ITVWEPL volume (−26.0 ± 6.3)%
smaller than the ITVG5, as result of tight margins in the lat-
eral direction to the beam and a margin increase for the
non-robust beam geometries in the beam direction (depth).
The margin size and expansion direction were assessed
from the COM variation and HD95 value. The mean
V95CTV over the course of the treatment when no margins
are applied was used as metric of the inter-fractional
changes per beam direction. Its correlation with the vari-
ation of the DSC and the HD95 between the CTV and the
ITVWEPL led to the selection of the HD95 as indicator of
range changes due to a positive linear relation (r = 0.78) ver-
sus the smaller correlation coefficient of the DSC (r = 0.63).
The analysis of the obtained ITVWEPL is presented in
terms of median and quartiles values in the Table 2 and
Fig. 5. For non-robust geometries (C and D) the margin
to apply to the CTV to cover the changes can be up to
10 mm in depth larger in the proximal edge of the beam
for the most patients, while the lateral direction to the
BEV requires less than 5 mm. Based on these results,
new plan optimizations were performed for an asymmetric
ITV (ITVAsy) that covers 75% of the dose distributions,
corresponding to a margin in the proximal direction of
10 mm and 7 mm, and of 6 mm and 3 mm in the distal
Table 1 V95CTV mean and standard deviation over all patients and per beam incidences and ITV-concepts
V95 (mean ± st.deviation) of the CTV
ITV Concept & Beam Configuration(A-F) A B C D E F
ITV0 95.6 ± 2.8 96.4 ± 2.7 88.7 ± 7.0 90.8 ± 5.6 98.0 ± 2.0 98.9 ± 1.5
ITV3 98.1 ± 1.7 98.6 ± 1.6 92.6 ± 6.4 94.0 ± 4.2 98.9 ± 1.7 99.5 ± 1.2
ITVHU3 98.1 ± 1.6 98.6 ± 1.6 92.6 ± 6.3 94.2 ± 4.1 99.1 ± 1.4 99.5 ± 1.2
ITV5 99.2 ± 1.2 99.4 ± 1.2 95.8 ± 5.2 96.7 ± 3.1 99.4 ± 1.3 99.6 ± 1.2
ITVHU5 99.2 ± 1.2 99.4 ± 1.2 95.8 ± 5.1 96.8 ± 3.0 99.4 ± 1.2 99.6 ± 1.2
ITVAsy - - 97.5 ± 3.9 98.1 ± 2.1 - -
Fig. 4 Evaluation of the CTV dose from the weekly dose distribution obtained from different optimizations. a V95CTV of the plan optimized to the
ITVG5 (dark grey boxes) and using the ITVAsy for the non-robust geometries. Each box represents 25-75% of the data, with the median value
represented as the solid line and the outlier as the dots. b Mean and standard deviation of the HCTV
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Fig. 5 (a1-a3) Variation of the ITVWEPL COM relative to the CTV in the longitudinal (a1), lateral (a2) and superior-inferior (a3) direction with respect
to beam’s-eye-view. b1) HD95% as function of the beam geometry, with each box showing 25-75% of the data. b2) Correlation, per beam direction,
between the CTV mean dose for the weekly CTs (plan optimized to the ITVG0) and the HD95
Table 2 Evaluation of the calculated ITVWEPL by: volume comparison with the ITVG5 (mean, minimum and maximum are shown);
directional expansion relative to the CTV (HD95%); COM variation relative to the CTV. The reported values as Q25% and Q75% correspond
respectively to the first and third quartiles of the data
ITVWEPL Characterization
Beam
Configuration
(A-F)
ΔV ITV5-ITVWEPL CTV expansion (mm) ΔCOM. Depth (mm) ΔCOM. Lateral (mm)
Mean (%) [Min-Max] (%) (Q75% of HD95%) [Q25%;Q75%] [Q25%;Q75%]
A, F1 −28.0 [−35.3,-22.6] 4.5 [−1.2; −0.3] [−0.2;0.3]
B,E2 −27.9 [−36.5,-22.1] 4.5 [−0.8 -0.5] [0;0.2]
C −16.9 [−30.5,-8.4] 10 [−5.3;2.8] [−0.2;0.5]
D,E1 −26.9 [−37.2,-15.5] 6.8 [−3.1;0.4] [0.1;0.7]
F2 −28.7 [−35.9,-21.4] 5.0 [−0.7;0.7] [−0.1;0.5]
Batista et al. Radiation Oncology  (2017) 12:94 Page 6 of 9
direction to cover the COM variations for the geometry C
and D, respectively. The delivery of these new plans to
each weekly-CT, showed an improvement of the V95CTV,
Fig. 4a.
For robust geometries the analysis showed to be suit-
able the use of a symmetric margin where 5 mm is
enough for 75% of the fractions.
Discussion
For the analyzed patients the tumor inter-fractional
changes are in agreement to the findings by Liu et al. [18]
who report changes in the COM in the order of 1–2 mm
with substantial changes in the tumor volume. Anatomical
changes in the healthy tissues were also detected along the
course of the treatment, with density changes in the bowel
and stomach and weight loss, resulting in drastic reduc-
tions of the V95CTV and homogeneity. Kumagai et al. [10]
pointed out variations on the D95 CTV of 10% due to
intra-fractional bowel changes using a passive delivery sys-
tem, which matches with our results using a single beam
in the anterior or lateral direction in the presence of inter-
fractional changes. An interesting study of Houweling et
al. [19] used alternatively the routinely acquired cone-
beam CT (CBCT) to assess the inter-fractional changes in
the patient anatomy, through dose calculations in a CT,
obtained by deformable registration of the planning CT to
these CBCTs. This method results in an increase of the
available data but the deformable registration adds new
uncertainties to the evaluation.
The influence of the range changes on dose to the
OARs was not part of our analysis and further investiga-
tion need to be included especially for geometries where
the OARs are in the beam distal edge.
We have demonstrated that the impact of inter-
fractional changes can be reduced to a large extent
with an adequate selection of the beam geometry and
ITV-margins. For the analyzed treatment fractions and
patients the use of a symmetric margin of 5 mm and
two posterior oblique beams was enough to keep the
CTV coverage above 95%, with 10% of the cases with a
V95CTV of 95-98%. Nevertheless, cases with substantial
changes in the CTV shape or location were detected, lead-
ing to a decrease in dose coverage (outliers in Fig. 4a). In
these cases, treatment plan adaption or re-planning might
be an option. Moreover, our results only considered uncer-
tainties resulting from anatomy changes and the uncertain-
ties from the patient positioning were neglected. Regarding
the patient positioning, studies from Jayachandran et al.
[20] showed that bone-matching registration might not ac-
curately predict the tumor location, and therefore suggests
the use of fiducial markers combined with daily soft-tissue
imaging.
The definition of PTV margins is beyond the scope of
this work which aimed to isolate the inter-fractional
motion impact. With exception of errors from the rigid
registration, other systematic errors, as example uncertain-
ties in Hounsfield units or patient positioning, do not have
an impact on our simulation results. However, they need
to be taken into account for clinical implementation.
An important scope of the study was to suggest clinic-
ally feasible approaches to increase the plan robustness to
account for range uncertainties. From the first attempt
with a symmetric range-uniform concept, the results
showed that a small margin of 3 or 5 mm was not enough
to overcome the uncertainties from non-robust beam con-
figurations. Hence, the use of asymmetric field specific
margins was evaluated, which was already investigated
by Park et al. [21] as an approach to mitigate range un-
certainties. Also, Miki et al. [22] investigated the use of
field-specific target and OARS but for the case of intra-
fractional changes. In our study, the obtained ITVWEPL,
based on Graeff et al. [11] study, preserves the CTV
coverage over the set of weekly-CTs, including the inter-
fractional anatomical changes. The obtained ITVWEPL
matched with the literature that suggests small lateral
margins and larger margins in the direction of the low
density tissues, that here correspond usually to the
proximal direction [21, 23].
Note that the ITVWEPL concept cannot be directly
used in the clinical routine since the complete information
of the inter-fractional changes along the treatment course
is not readily available at the planning stage. However, we
have used this approach to guide the definition of an
asymmetric standard margin for future patients. The sug-
gested asymmetric margins were tested for the non-robust
geometries and showed a V95CTV improvement face to
the symmetric concept. The validation of this concept in a
different cohort of patient remains to be shown and will
be investigated in a future study. Furthermore, this con-
cept could be applied clinically e.g. in a boost treatment,
where several planning CTs have been obtained in the first
treatment sessions with photons.
Our study was tailored to improve the treatment plan
robustness against inter-fractional changes using IMPT
optimized plans. However, a comparison of the plan
quality using SFUD and IMPT is suggested prior to the
implementation of this technique in others facilities, since
the degree of plan modulation can compromise the ro-
bustness. In our study, all the plans represented reduced
modulation. Therefore the results might be extended to
SFUD optimizations.
Intra-fractional changes were not investigated and will
require an additional expansion of the target volume
[24]. Larger margins alone are not a solution for scanned
ion therapy since interplay effects will have an impact on
the dose coverage and homogeneity throughout the
complete volume [25, 26]. Shiomi et at. [27] evaluated,
how the use of specific beam directions might increase
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the plan robustness for the case of passive and active
delivery systems. Moreover, a complementary approach
is the use of abdominal compression to reduce the motion
amplitude and additional beam rescanning to mitigate the
interplay effect [28]. There is no consensus on the quanti-
fication of intra-fractional motion in pancreas [18, 29]
among the studies, and a separated study will be con-
ducted to assess the need of mitigation techniques. This
might include the use of beam-gating [30] or other modi-
fied beam delivery strategies, as well the use of 4D opti-
mized plans [31] or quantification of range variations
based on daily CT imaging [32].
Conclusion
In conclusion, the combination of two oblique posterior
beams for scanned carbon-ion treatment of pancreatic
cancer with the simple concept of an isotropic CTV-ITV
margin of 5 mm can substantially reduce the dosimetric
impact of inter-fractional changes and yields to acceptable
dose coverage for most patients and fractions. The use of
WEPL-based margins can reduce the required margins
even more, but this technique will require a daily monitor-
ing of the anatomical changes. Therefore, range variations
may be large and routine soft-tissue imaging and adaption
strategies will likely improve the treatment. Population-
based asymmetric ITV margins may be a feasible clinical
strategy to account for density changes and to reduce the
irradiated volume as well as to assess the validity of the se-
lected margins for a defined beam path direction.
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